FDA approves Perrigo angina pectoris drug
ALLEGAN, Mich. — The Food and Drug Administration has approved a drug made by Perrigo Co. for treating heart disease, the company said Monday.
The FDA approved Perrigo’s nitroglycerin lingual spray in the 400-mcg-per-spray strength. The drug is used to relieve attacks of or prevent angina pectoris due to coronary artery disease.
The drug is a generic version of Arbor Pharmaceuticals’ Nitrolingual Pumpspray, which has sales of about $65 million, according to Perrigo. As the first company to win approval for the generic version, Perrigo has 180 days in which to compete exclusively against Arbor.
Teva launches generic niacin extended-release tablets
JERUSALEM — Teva Pharmaceutical Industries has launched a generic drug for treating cardiovascular disease, the company said.
Teva announced the launch of niacin extended-release tablets in the 500-mg, 750-mg and 1,000-mg strengths. As the first company to file for approval of the drug, Teva will have 180 days in which to market the generic version exclusively.
The drug is a generic version of AbbVie’s Niaspan, used to treat elevated low-density lipoprotein or "bad" cholesterol, triglycerides and other lipids in the blood. Niaspan had sales of about $1.12 billion during the 12 months ended in June, according to IMS Health.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Hospira announces new executive appointment
LAKE FOREST, Ill. — Generic drug maker Hospira has appointed Matt Stober as its SVP operations, the company said.
Stober, who began working for Hospira in 2011 as corporate VP U.S. pharmacy operations, will have expanded leadership over all the company’s drug manufacturing, as well as manufacturing science and technology, engineering, competitive strategy, health and safety, supply chain and procurement. Stober succeeds John Elliot, who has led operations since April 2012 and will provide continuity of support until he retires at the end of the year.
"Matt brings the perfect blend of vision and experience to our operations organization, backed by a proven track record of success at Hospira," CEO F. Michael Ball said. "In his expanded role, we’re confident Matt will continue to successfully advance our dual commitment to remediate and modernize our processes and operations while delivering patient-critical products and ultimately establish our manufacturing operations as a strategic, competitive advantage."